MAIA Biotechnology (MAIA)

• Market cap: $85.5M
• 1 day: 5.22%
• 5 days: 13.71%
• 1 month: 9.3%
• 3 months: -34.11%
• 6 months: 28.18%
• Year to date: -11.88%
• 1 year: -26.18%
• 5 years: -68.39%
• 10 years: -68.39%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

Employees: 13